
Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed ...
Ankyra Therapeutics announced preliminary clinical data today from Part 1 of their Phase 1 ANCHOR study evaluating an anchored IL-12 drug conjugate, tolododekin alfa, as monotherapy in patients with solid tumors Ankyra also announced the first patient has …